tbuckley/cabot-search huggingface dataset:
Abstract 17948: Endothelial Cell Infusion Improves Chronic Kidney Disease-induced Endothelial Dysfunction in 5/6 Nephrectomized Rats
Authors: Maricica Pacurari, Rob H Hilgers, Dongqi Xing, Suzanne Oparil, Yiu-Fai Chen, Fadi G Hage
Journal: Circulation (2012)

Introduction:  Chronic kidney disease (CKD) increases risk of cardiovascular disease (CVD). Endothelial dysfunction, an early step in development of CVD, is prevalent in CKD. This study tested the hypothesis that transfusion of rat aortic endothelial cells (EC), via increasing nitric oxide synthase (NOS) activity, improves vascular reactivity in a rat model of CKD.   Methods and Results:  Male Sprague-Dawley rats (11 wk) underwent sham surgery (S) or 5/6 nephrectomy (Nx). Six wks after Nx, EC (1.5 x 106 cells/rat) or vehicle (Nx+Veh) were transfused intravenously. One wk later, vascular reactivity of mesenteric artery was assessed on a wire myograph. Sensitivity of endothelium-dependent relaxation to acetylcholine (ACh) and maximum vasodilation (Emax to 10 μ M ACh) were impaired by Nx and improved by EC transfusion (Fig A, B). Emax was negatively correlated with serum creatinine (r= -0.55, p   Conclusion:  EC transfusion attenuates CKD-induced endothelium-dependent vascular dysfunction by regulating DDAH expression and enhancing eNOS and nNOS activities. These results suggest that EC-based therapy could provide a novel therapeutic strategy to improve vascular function in CKD.
Stereotactic body radiotherapy for hepatocellular carcinoma in patients with poor liver function.
Authors: Jason Chan, Spencer Behr, Jonathan Pai, Mary Uan-Sian Feng, Albert Chang, Daphne A. Haas-Kogan, Mekhail Anwar
Journal: Journal of Clinical Oncology (2018)

397 Background: Stereotactic body radiation therapy (SBRT) may benefit patients with hepatocellular carcinoma (HCC) who are not candidates for other liver-directed therapies due to poor liver function (plf). However, optimal patient selection, safety, and efficacy of SBRT in plf-HCC patients are not known. We studied dosimetric, baseline liver function, and radiographic features at the time of treatment that may help identify HCC patients with liver dysfunction who would benefit most from SBRT. Methods: Medical records of plf-HCC patients with cirrhosis treated with SBRT at a single institution between 2013-2016 were reviewed. Prescription doses were tailored to liver function based on INR and total bilirubin (tBili) and uninvolved liver volume. Time to local progression was evaluated using cumulative incidence analysis (Gray’s test) and competing risks regression analysis. Local progression was defined using RECIST criteria. Overall survival was estimated using the Kaplan-Meier method and Cox proportional hazards model. Results: 26 plf-HCC patients with median baseline MELD 11 (range 1-35), tBili 1.6 (0.5-6.5), INR 1.2 (1.0-9.0), tumor size of 4.1 cm (1.7-8.5 cm), and liver volume 1251 cc (596-2322 cc) were treated with SBRT. 54% received SBRT for retreatment of the same tumor. Patients were heavily pretreated with 50%, 19%, and 8% previously receiving TACE, ethanol ablation, and RFA, respectively. With a median prescription of 30 Gy (8-50 Gy) in 5 fractions (2-5), the median liver dose was 8 Gy (3-14 Gy). Median increase in MELD 90 days post-SBRT was 1.1 (0-19), with 35% experiencing no increase and 25% increasing &gt;2.5. Local control (LC) was 55% at 6 months with one patient bridged to liver transplant. LC was not associated with improved survival (p = 0.39) and median overall survival (MS) was 8.6 months (0.9-31.7 mo). However, longer MS was seen for patients without ascites (MS=16.5 vs. 4.1 mo, p = 0.005), tBili &lt; 2 (MS=16.5 vs. 5.2 mo, p = 0.015) and MS was not reached in patients treated to &gt; 30 Gy (p = 0.04) or with MELD &lt; 11 (p = 0.02). Conclusions: In this cohort of HCC patients with poor liver function, the absence of ascites, tbili &lt; 2, and lower MELD scores were associated with improved survival following SBRT.
Cost-effectiveness of Skin Cancer Referral and Consultation Using Teledermoscopy in Australia
Authors: Centaine L. Snoswell, Liam J. Caffery, Jennifer A. Whitty, H. Peter Soyer, Louisa G. Gordon
Journal: JAMA Dermatology (2018)

International literature has shown that teledermoscopy referral may be a viable method for skin cancer referral; however, no economic investigations have occurred in Australia.To assess the cost-effectiveness of teledermoscopy as a referral mechanism for skin cancer diagnosis and management in Australia.Cost-effectiveness analysis using a decision-analytic model of Australian primary care, informed by publicly available data.We compared the costs of teledermoscopy referral (electronic referral containing digital dermoscopic images) vs usual care (a written referral letter) for specialist dermatologist review of a suspected skin cancer.Cost and time in days to clinical resolution, where clinical resolution was defined as diagnosis by a dermatologist or excision by a general practitioner. Probabilistic sensitivity analysis was performed to examine the uncertainty of the main results.Findings from the decision-analytic model showed that the mean time to clinical resolution was 9 days (range, 1-50 days) with teledermoscopy referral compared with 35 days (range, 0-138 days) with usual care alone (difference, 26 days; 95% credible interval [CrI], 13-38 days). The estimated mean cost difference between teledermoscopy referral (A$318.39) vs usual care (A$263.75) was A$54.64 (95% CrI, A$22.69-A$97.35) per person. The incremental cost per day saved to clinical resolution was A$2.10 (95% CrI, A$0.87-A$5.29).Using teledermoscopy for skin cancer referral and triage in Australia would cost A$54.64 extra per case on average but would result in clinical resolution 26 days sooner than usual care. Implementation recommendations depend on the preferences of the Australian health system decision makers for either lower cost or expedited clinical resolution. Further research around the clinical significance of expedited clinical resolution and its importance for patients could inform implementation recommendations for the Australian setting.
TCTAP A-109 Safety of Longer Size Stent in Treating De Novo Long Coronary Lesion - No ISR at 1.6-year Follow-Up: Experiences at Our Center
Authors: Shams Munwar, Ahm Waliul Islam, Azfar H. Bhuiyan, Tamzeed Ahmed, A.Q.M. Reza, Shahab Uddin Talukder
Journal: Journal of the American College of Cardiology (2018)
Additional Risk Factors for Breast Implant–Associated Anaplastic Large Cell Lymphoma
Authors: Kadri Altundag
Journal: JAMA Surgery (2018)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Surgery HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Surgery journal
Methods for Evaluating Natural Experiments in Obesity
Authors: Wendy L. Bennett, Renee F. Wilson, Allen Zhang, Eva Tseng, Emily A. Knapp, Hadi Kharrazi, Elizabeth A. Stuart, Oluwaseun Shogbesan, Eric B. Bass, Lawrence J. Cheskin
Journal: Annals of Internal Medicine (2018)

Given the obesity pandemic, rigorous methodological approaches, including natural experiments, are needed.To identify studies that report effects of programs, policies, or built environment changes on obesity prevention and control and to describe their methods.PubMed, CINAHL, PsycINFO, and EconLit (January 2000 to August 2017).Natural experiments and experimental studies evaluating a program, policy, or built environment change in U.S. or non-U.S. populations by using measures of obesity or obesity-related health behaviors.2 reviewers serially extracted data on study design, population characteristics, data sources and linkages, measures, and analytic methods and independently evaluated risk of bias.294 studies (188 U.S., 106 non-U.S.) were identified, including 156 natural experiments (53%), 118 experimental studies (40%), and 20 (7%) with unclear study design. Studies used 106 (71 U.S., 35 non-U.S.) data systems; 37% of the U.S. data systems were linked to another data source. For outcomes, 112 studies reported childhood weight and 32 adult weight; 152 had physical activity and 148 had dietary measures. For analysis, natural experiments most commonly used cross-sectional comparisons of exposed and unexposed groups (n = 55 [35%]). Most natural experiments had a high risk of bias, and 63% had weak handling of withdrawals and dropouts.Outcomes restricted to obesity measures and health behaviors; inconsistent or unclear descriptions of natural experiment designs; and imperfect methods for assessing risk of bias in natural experiments.Many methodologically diverse natural experiments and experimental studies were identified that reported effects of U.S. and non-U.S. programs, policies, or built environment changes on obesity prevention and control. The findings reinforce the need for methodological and analytic advances that would strengthen evaluations of obesity prevention and control initiatives.National Institutes of Health, Office of Disease Prevention, and Agency for Healthcare Research and Quality. (PROSPERO: CRD42017055750).
Long-term evolution of thrombocytopenia in patients with chronic hepatitis C and advanced fibrosis after sustained virological response with direct antiviral agents
Authors: J. Gómez-Camarero, P. Linares, S. Calvo, M.I. Martín Arribas, C. Almohalla, F. Jorquera, H.A.R. Rosario, F. Jiménez Vicente, M. de Benito, Belén B. Cabredo, Begoña A. Cuenllas, E. Badia-Aranda, F. Sáez-Royuela
Journal: Journal of Hepatology (2018)
Continuous infusion of beta-lactam antibiotics in cirrhotic patients with bloodstream infection: results from a prospective multicentre observational study
Authors: M. Bartoletti, M. Giannella, R. Lewis, S. Tedeschi, G. Verucchi, P. Caraceni, M.T. Cerenzia, E.M. Seminari, T. Bruns, M. Merli, P. Burra, A.E. Maraolo, C. Schramm, N. Cobos-Tigueros, M. Paul, J. Rodríguez-Bano, M. Bernardi, P. Viale
Journal: Journal of Hepatology (2018)
Temsirolimus (TEM) and lenalidomide (LEN) in relapsed/refractory Hodgkin lymphoma including in patients with prior exposure to brentuximab vedotin (BV).
Authors: Jagoda Jasielec, Amy Sarah Kimball, Kenneth Stuart Cohen, Justin Paul Kline, Aaron Rapoport, Adam Matthew Petrich, Chadi Nabhan, Sachdev Thomas, Laurence A. Doyle, Walter Michael Stadler, Theodore Karrison, Sonali M. Smith
Journal: Journal of Clinical Oncology (2014)

8567 Background: Hodgkin lymphoma (HL) patients (pts) ineligible for or relapsed after transplant pose a considerable treatment (tx) challenge. While BV is an active agent in this setting, HL remains incurable and new therapies are needed. The PI3K/Akt/mTOR axis and the microenvironment are rational targets in HL. We previously reported phase I results of a phase I/II study of TEM and LEN across lymphoma subtypes demonstrating good tolerability (J Clin Oncol 30, 2012 abstr 8075). Here we report the results of an interim analysis of HL patients. Methods: NCI8309 is a multi-institutional phase II trial with 3 cohorts. Cohort C includes R/R HL.Key inclusion criteria are: ANC > 1,000/uL, platelets > 75,000/uL, normal renal and hepatic function, ECOG performance status of ≤2. Pts receive TEM 25 mg IV weekly and LEN 20 mg orally on D1-D21, q28 days until progression/intolerability up to 1 year. Responses are evaluated using the Cheson 2007 criteria at 2 months (mos), then every 3 mos thereafter. Results: Thirteen pts (8 male, 5 female) with a median age of 32 years (range, 23-53) were enrolled and evaluable. Pts received a median of 4 prior therapies (range, 2-11); 5 had prior radiation, 8 had prior autologous stem cell transplant (ASCT), and two received both ASCT and an allogeneic transplant. Importantly, 11/13 pts relapsed after BV. With a median follow-up of 9 mos, pts received a median of 4 cycles (range, 2-11) of therapy. The best overall response rate was 85%: 5 (38%) complete responses, 6 (46%) partial responses, 1 (8%) stable disease; median time to best response was 2 cycles. One pt progressed prior to planned evaluation and subsequently died of disease. Of the remaining 12 pts, 5 eventually progressed and 4 went on to transplant including 1 pt with progressive disease. The most common grade 1/2 toxicities included hyperglycemia (77%), fatigue (70%), and LFT abnormalities (77%). The most common grade 3/4 toxicities were neutropenia (46%), thrombocytopenia (38%), and lymphopenia (38%). Conclusions: The combination of TEM plus LEN shows promising activity in R/R HL, including prior BV exposure or failure and warrants further evaluation. Clinical trial information: NCT01076543.
<i>MYD88</i> L265P Mutation in Lymphoid Malignancies
Authors: Xinfang Yu, Wei Li, Qipan Deng, Ling Li, Eric D. Hsi, Ken H. Young, Mingzhi Zhang, Yong Li
Journal: Cancer Research (2018)

Abstract Next-generation sequencing has revealed cancer genomic landscapes, in which over 100 driver genes that, when altered by intragenic mutations, can promote oncogenesis. MYD88 is a driver gene found in hematologic B-cell malignancies. A missense mutation (L265P) changing leucine at position 265 to proline in MYD88 is found in ∼90% of Waldenström macroglobulinemia (WM) cases and in significant portions of activated B-cell diffuse large B-cell lymphomas and IgM monoclonal gammopathy of undetermined significance. Few cancers such as WM have a single amino acid substitution in one gene like MYD88 L265P that occurs in ∼90% of cases, making WM paradigmatic for study of a single causative mutation in oncogenesis. In this review, we summarize the frequency and cancer spectrum of MYD88 L265P and its downstream effects in lymphoid cancers. Malignant B cells with MYD88 L265P are likely transformed from IgM-producing B cells either in response to T-cell–independent antigens or in response to protein antigens before class switching. We also discuss therapeutic strategies that include targeting Bruton tyrosine kinase and other kinases, interfering with the assembly of MYD88 and its interacting partners, and MYD88 L265P-specific peptide-based immunotherapy. Cancer Res; 78(10); 2457–62. ©2018 AACR.
Resection of large sessile serrated polyps by cold piecemeal endoscopic mucosal resection: Serrated COld Piecemeal Endoscopic mucosal resection (SCOPE)
Authors: Rajaratnam Rameshshanker, Zacharias Tsiamoulos, Andrew Latchford, Morgan Moorghen, Brian Saunders
Journal: Endoscopy (2018)

Sessile serrated adenomas/polyps (SSA/Ps) are frequently found in the proximal colon, where the wall is thinner and easily damaged by diathermy during polypectomy, which also carries a risk of delayed bleeding, perforation, and post-polypectomy syndrome. SSA/Ps are often flat with subtle, irregular edges making endoscopic assessment of their extent difficult [1]. This can lead to incomplete resection and risk of post-colonoscopy cancer [2].
P254Comparison of the transcriptome of human mesenchymal cells isolated from right ventricle and epicardial fat
Authors: J Stepniewski, U Florczyk, K Bukowska-Strakova, K Szade, T Cichon, M Mikula, M Zembala, M Zembala, A Jozkowicz, J Dulak
Journal: Cardiovascular Research (2018)

contribute to the complex phenotype.Further comprehensive functional studies are required to evaluate the possible role of SYNM mutations in development of ulnar-mammary syndrome and ventricular arrhythmias. P251Genomic microimbalances in children with combined congenital heart and kidney defects
TCTAP C-224 Successful Valve-in-valve Transcatheter Aortic Valve Replacement with Bioprosthetic Valve Fracture
Authors: Sang Yong Om, Yong-Hoon Yoon, Minsoo Kim, Hanbit Park, Sang-Cheol Cho, Sangwoo Park, Tae-Oh Kim, Sun Hack Lee, Osung Kwon, Kyusup Lee, Do-Yoon Kang, Jung-Min Ahn, Duk-Woo Park, Soo-Jin Kang, Seung-Whan Lee, Young-Hak Kim, Cheol Whan Lee, Seong-Wook Park, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2018)
Dysmetabolic iron overload syndrome: The need for an accurate liver iron concentration determination by magnetic resonance imaging
Authors: Agustin Castiella, José M. Alústiza, Eva Zapata, Leire Zubiaurre, Pedro Otazua, José I. Emparanza
Journal: Hepatology (2017)

Potential conflict of interest: Nothing to report. To the Editor: We have read with great interest the article by Lainé et al.1 They concluded that in dysmetabolic iron overload syndrome patients, iron depletion by phlebotomy did not improve metabolic and hepatic features, was not well tolerated, and was associated with weight gain. In their study, dysmetabolic iron overload syndrome patients had a liver iron concentration (LIC) >50 μmol/g by magnetic resonance imaging.2 Our group3 has published a study that provides further evidence that LIC is not raised in patients with hyperferritinemia and metabolic syndrome. Patients with dysmetabolic hyperferritinemia (metabolic syndrome and hyperferritinemia) have a mean LIC within normal values, and LIC in patients with dysmetabolic hyperferritinemia have no significant differences from patients with hyperferritinemia and without metabolic syndrome. This points toward the importance of ferritin as a marker of inflammation rather than clinically important hepatic iron deposition and provides caution when interpreting these values and making subsequent clinical management decisions, for example, whether to perform a phlebotomy.4 The LIC determination in Lainé et al.'s study1 was performed by magnetic resonance imaging, using Rennes University's calculation model.2 This method has a tendency to overestimate LIC, which limits the diagnostic performance and accuracy for clinical practice.5 In a study with 171 biopsied patients, 43% of patients with no iron overload were diagnosed using MRI as having liver iron overload and 45% of patients with moderate iron overload were diagnosed as having high iron overload. The specificity for the absence of liver iron overload was 57%.5 We can expect that an important group of Lainé et al.'s 274 patients may have been overestimated for LIC values. Probably, the real LIC values were lower than those published.
Role of Extracellular Vesicles in Viral and Bacterial Infections: Pathogenesis, Diagnostics, and Therapeutics
Authors: Meryl Rodrigues, Jia Fan, Christopher Lyon, Meihua Wan, Ye Hu
Journal: Theranostics (2018)

Extracellular vesicles (EVs), or exosomes, are nanovesicles of endocytic origin that carry host and pathogen-derived protein, nucleic acid, and lipid cargos.They are secreted by most cell types and play important roles in normal cell-to-cell communications but can also spread pathogen-and host-derived molecules during infections to alter immune responses and pathophysiological processes.New research is beginning to decipher how EVs influence viral and bacterial pathogenesis.In this review, we will describe how EVs influence viral and bacterial pathogenesis by spreading pathogen-derived factors and how they can promote and inhibit the immune response to these pathogens.We will also discuss the emerging potential of EVs as diagnostic and therapeutic tools.
Propranolol treatment associated with better survival and reduced sepsis in cirrhotic patients with hepatic encephalopathy
Authors: P.-C. Lee, Y.-J. Chen, C.-W. Su, Y.-C. Cho, P.-H. Chen, W.-Y. Kao, Y.-H. Huang, H.-C. Lin, M.-C. Hou, J.-C. Wu
Journal: Journal of Hepatology (2018)
Diffusion-weighted MRI in inflammatory bowel disease
Authors: Lieven Pouillon, Valérie Laurent, Marc Pouillon, Peter Bossuyt, Christiana Bonifacio, Silvio Danese, Parakkal Deepak, Edward V Loftus, David H Bruining, Laurent Peyrin-Biroulet
Journal: The Lancet. Gastroenterology & hepatology (2018)
Development of scientific exercise guidelines for adults with spinal cord injury
Authors: Victoria L Goosey-Tolfrey, Jan W van der Scheer, Jan Lexell, Kristen Clements, Kathleen A Martin Ginis
Journal: British Journal of Sports Medicine (2018)

In 2016, an international team was established, to systematically review and build on previous bodies of work,1 2 to form evidence-based scientific guidelines.3 Presented in the infographic are the steps and outcomes from this work. This project brought together people from …
Mitochondrial Translation Efficiency Controls Cytoplasmic Protein Homeostasis
Authors: Tamara Suhm, Jayasankar Mohanakrishnan Kaimal, Hannah Dawitz, Carlotta Peselj, Anna E. Masser, Sarah Hanzén, Matevž Ambrožič, Agata Smialowska, Markus L. Björck, Peter Brzezinski, Thomas Nyström, Sabrina Büttner, Claes Andréasson, Martin Ott
Journal: Cell Metabolism (2018)
First clinical evaluation in chronic hepatitis B patients of the synthetic farnesoid X receptor agonist EYP001
Authors: R. Erken, F. Stelma, E. Roy, S. Diane, P. Andre, J. Vonderscher, M. Eric, S. Tim, P. Philippe, L. Christian, P. Scalfaro, H. Reesink, C.M. Sousa, E. Jacob
Journal: Journal of Hepatology (2018)
Hospitals do not recognise dementia in a third of patients admitted with other conditions
Authors: Ingrid Torjesen
Journal: BMJ (2018)

Hospitals fail to recognise dementia in a third of patients who have already had the condition diagnosed if they are admitted to hospital for a different reason, a UK study has found.

Researchers at University College London reviewed data on 21 387 patients aged over 65 who had been assessed at South London and Maudsley NHS Foundation Trust memory clinics from 2008 to 2016. A total of 8246 people had dementia diagnosed and were then admitted to general hospitals 37 329 times after their diagnosis.

The results, published in Alzheimer’s and Dementia ,1 showed that 6429 patients (78% (95% confidence interval 77.1% to …
A kindred with mutant IKAROS and autoimmunity
Authors: Erika Van Nieuwenhove, Josselyn E. Garcia-Perez, Christine Helsen, Princess D. Rodriguez, Pauline A. van Schouwenburg, James Dooley, Susan Schlenner, Mirjam van der Burg, Els Verhoeyen, Rik Gijsbers, Seth Frietze, Hilde Schjerven, Isabelle Meyts, Frank Claessens, Stephanie Humblet-Baron, Carine Wouters, Adrian Liston
Journal: Journal of Allergy and Clinical Immunology (2018)
A-to-I RNA Editing Contributes to Proteomic Diversity in Cancer
Authors: Xinxin Peng, Xiaoyan Xu, Yumeng Wang, David H. Hawke, Shuangxing Yu, Leng Han, Zhicheng Zhou, Kamalika Mojumdar, Kang Jin Jeong, Marilyne Labrie, Yiu Huen Tsang, Minying Zhang, Yiling Lu, Patrick Hwu, Kenneth L. Scott, Han Liang, Gordon B. Mills
Journal: Cancer Cell (2018)
Serum bile acids are markedly elevated in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH)
Authors: A. Sanyal, S. Harrison, M. Charlton, S. Caldwell, J. Chuang, L. Wang, G. Chen, C. Chung, S. Djedjos, R. Myers, N. Afdhal, J. Bosch, V. Ratziu, R. Loomba
Journal: Journal of Hepatology (2018)
Response by Søgaard et al to Letter Regarding Article, “Pericarditis as a Marker of Occult Cancer and a Prognostic Factor for Cancer Mortality”
Authors: Kirstine Kobberøe Søgaard, Dóra Körmendiné Farkas, Vera Ehrenstein, Krishnan Bhaskaran, Hans Erik Bøtker, Henrik Toft Sørensen
Journal: Circulation (2018)
Does reduced zona pellucida binding protein 2 (ZPBP2) expression on chromosome 17q21 protect against asthma?
Authors: Marina Miller, Christine Vuong, Meghan Farrell Garcia, Peter Rosenthal, Sudipta Das, Ning Weng, Alexa Pham, Yu Jin Kim, David H Broide
Journal: Journal of Allergy and Clinical Immunology (2018)